Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
about
Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-AnalysisOptimizing the Clinical Use of VancomycinDoes contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceThe safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysisAn alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Biologic concentration testing in inflammatory bowel disease.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Optimization of anti-infective dosing regimens during online haemodiafiltrationDaily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients.Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study.Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.
P2860
Q26770913-7DA907F8-8540-45A6-8C0C-0BCA491793C9Q28069334-197B6750-067B-4CB6-9BF4-3ABA26CBE143Q30828312-9AF022D0-BA6D-4A30-8CED-BA7A275A32E5Q34274190-4E825AC9-A23D-46AA-B548-D1797C2B81F9Q36077880-FF40E6EB-D0E9-45FA-BE49-1E5774CE0DFCQ36083619-07A53B8C-3E18-4985-B090-3FBC2E63DEA0Q36089167-1D6F94F4-BE45-45A1-A1E9-66A55AEB7EBFQ36148828-0BA4F105-2CA2-4B87-A7DB-37F99A2598A4Q37563029-2EAD949A-4D14-4864-9EA0-96684DC0F33DQ38319306-3F0FD553-B518-4A65-9F3C-A1EAE3F0C89AQ38790740-93866F7B-2332-40C6-9BEE-415DD0CB13C4Q38843412-0B9433A7-A0DA-4FA6-8666-8E873094050CQ38882052-924B17F7-C7EF-49BA-9893-C40B9F588DF3Q39061989-993DF654-F339-4C9A-B0AA-78F067204BE4Q40441139-69E2BD6E-7DB0-4E58-9AC0-531641E55FBAQ40716347-EE00E344-57C0-42AB-A893-C76CD9978B6EQ41410382-AFB8C64F-EC19-4D23-9C0B-6DF393117C9FQ47689239-5C03FAF4-7C92-4443-B1BC-B347B0D363C4Q55393633-5FA50EA9-C6F0-41B4-B60E-B98985DDE21F
P2860
Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Vancomycin pharmacodynamics an ...... ureus-associated septic shock.
@en
Vancomycin pharmacodynamics an ...... ureus-associated septic shock.
@nl
type
label
Vancomycin pharmacodynamics an ...... ureus-associated septic shock.
@en
Vancomycin pharmacodynamics an ...... ureus-associated septic shock.
@nl
prefLabel
Vancomycin pharmacodynamics an ...... ureus-associated septic shock.
@en
Vancomycin pharmacodynamics an ...... ureus-associated septic shock.
@nl
P2093
P50
P1476
Vancomycin pharmacodynamics an ...... ureus-associated septic shock.
@en
P2093
Anand Kumar
Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group
Ethan Rubinstein
Peter Dodek
Yazdan Mirzanejad
P304
P356
10.1016/J.IJANTIMICAG.2012.10.015
P577
2013-01-09T00:00:00Z